330 related articles for article (PubMed ID: 26052866)
1. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
Lip GY; Halperin JL; Petersen P; Rodgers GM; Pall D; Renfurm RW
J Thromb Haemost; 2015 Aug; 13(8):1405-13. PubMed ID: 26052866
[TBL] [Abstract][Full Text] [Related]
2. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Weitz JI; Connolly SJ; Patel I; Salazar D; Rohatagi S; Mendell J; Kastrissios H; Jin J; Kunitada S
Thromb Haemost; 2010 Sep; 104(3):633-41. PubMed ID: 20694273
[TBL] [Abstract][Full Text] [Related]
3. Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
Eriksson BI; Agnelli G; Gallus AS; Lassen MR; Prins MH; Renfurm RW; Kashiwa M; Turpie AG
Thromb Haemost; 2014 Feb; 111(2):213-25. PubMed ID: 24136153
[TBL] [Abstract][Full Text] [Related]
4. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Steg PG; Mehta SR; Jukema JW; Lip GY; Gibson CM; Kovar F; Kala P; Garcia-Hernandez A; Renfurm RW; Granger CB;
Eur Heart J; 2011 Oct; 32(20):2541-54. PubMed ID: 21878434
[TBL] [Abstract][Full Text] [Related]
5. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE
J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472
[TBL] [Abstract][Full Text] [Related]
6. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
Xu H; Ruff CT; Giugliano RP; Murphy SA; Nordio F; Patel I; Shi M; Mercuri M; Antman EM; Braunwald E
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908401
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Norby FL; Bengtson LGS; Lutsey PL; Chen LY; MacLehose RF; Chamberlain AM; Rapson I; Alonso A
BMC Cardiovasc Disord; 2017 Sep; 17(1):238. PubMed ID: 28874129
[TBL] [Abstract][Full Text] [Related]
9. Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis.
Chan YH; Lee HF; Chao TF; Wu CT; Chang SH; Yeh YH; See LC; Kuo CT; Chu PH; Wang CL; Lip GYH
Cardiovasc Drugs Ther; 2019 Dec; 33(6):701-710. PubMed ID: 31745687
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
11. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Kadokura T; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):1-9. PubMed ID: 23754514
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
13. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.
Yamashita T; Koretsune Y; Yasaka M; Inoue H; Kawai Y; Yamaguchi T; Uchiyama S; Matsumoto M; Ogawa S
Circ J; 2012; 76(8):1840-7. PubMed ID: 22664798
[TBL] [Abstract][Full Text] [Related]
14. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
Petersen P; Grind M; Adler J;
J Am Coll Cardiol; 2003 May; 41(9):1445-51. PubMed ID: 12742279
[TBL] [Abstract][Full Text] [Related]
15. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
[TBL] [Abstract][Full Text] [Related]
16. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153
[TBL] [Abstract][Full Text] [Related]
18. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
[TBL] [Abstract][Full Text] [Related]
19. Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation.
Chan YH; Chuang C; Chan CC; Lee HF; Huang YC; Huang YT; Chang SH; Wang CL; Chao TF; Kuo CT; Yeh YH; Chen SA
Cardiovasc Diabetol; 2020 Mar; 19(1):30. PubMed ID: 32156277
[TBL] [Abstract][Full Text] [Related]
20. Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studies.
Fuji T; Nakamura M; Takeuchi M
Clin Appl Thromb Hemost; 2014 Mar; 20(2):199-211. PubMed ID: 22952213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]